Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Employment/Membership › Details

SOM Biotech–Casellas M: management, 202106– CFO before Ysios Capital Partners + Danone Group + PwC Consulting

 

Period Period 2021-06-23
Organisations Organisation SOM Innovation Biotech S.L. (SOM Biotech)
  Organisation 2 Ysios Capital Partners SGECR S.A.
  Group Ysios Capital (Group)
Products Product biopharmaceutical
  Product 2 venture capital
Person Person Casellas, Marc (SOM Biotech 202106– CFO before Ysios Capital Partners + Danone Group + PwC Consulting)
     

SOM Biotech S.L.. (6/23/21). "Press Release: SOM Biotech Appoints Marc Casellas as Chief Financial Officer". Barcelona.

SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases of the Central Nervous System, announces the appointment of Marc Casellas as Chief Financial Officer.

Mr Casellas has an extensive finance experience across the healthcare and venture capital sectors, specially in providing financing to life science companies at different stages of growth. Prior to joining SOM Biotech, Marc Casellas most recently served as Chief Financial Officer of Ysios Capital after holding finance positions at Danone Group and PwC Consulting. 

Raúl Insa, CEO of SOM Biotech highlights: “Marc Casellas has a deep expertise in managing finance in biotech and in venture capital. He will provide all aspects of financial and administration leadership in support of driving value creation. It is a great time to incorporate Marc Casellas to our team, to further align financial strategy with our corporate goals. We look forward to strengthening our management team as we enter our next phase of growth.”


About SOM Biotech: 

SOM Biotech (www.sombiotech.com) – established in 2009 – is a biopharmaceutical company based in Barcelona, Spain. SOM has an extensive portfolio of products that includes drugs for orphan diseases including TTR Amyloidosis, Huntington's disease, Phenylketonuria, Niemann-Pick C, Glioblastoma and Parkinson’s disease. The company engages in accelerated discovery of therapies through a proprietary artificial intelligence-based computational technology (SOMAI PRO) and develops strategic partnerships with major research centers and pharmaceutical companies.


Katja Görnemann
Investor Relations & Corporate Communication
Tel: +34 696135428

   
Record changed: 2021-06-23

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for SOM Innovation Biotech S.L. (SOM Biotech)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top